echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Roche and Teva reach innovative strategic cooperation to expand blood and tumor pipeline

    Roche and Teva reach innovative strategic cooperation to expand blood and tumor pipeline

    • Last Update: 2022-05-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Roche Pharma China announced on April 18 that it has reached a cooperation with Teva Pharmaceuticals (hereinafter referred to as "Teva") to expand the patient access of bendamustine orthohydrochloride-Cunda® in China.


    Left: Mr.


    Cunda® is the original research and development of bendamustine hydrochloride independently developed by Teva, which was approved in China in 2018 for the treatment of patients with disease progression during/after treatment with rituximab or rituximab-containing regimens.


    Compared with the 5-year survival rate of about 70% in developed countries, the 5-year survival rate of Chinese lymphoma patients is still only 39%, which requires more innovative drugs and more standardized diagnosis and treatment


    The cooperation between Roche and Teva will better leverage the synergistic effect of the original research + original research, and bring good survival benefits to the majority of Chinese lymphoma patients


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.